Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HN2302 in Refractory Myasthenia Gravis
NCT07413835Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of HN2302 in myasthenia gravis (MG), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 3 months. Started Mar 2026; status: recruiting.
02
Drugs
HN2302
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07413835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07413835.